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Tigecycline Induction of Phenol-Soluble Modulins by Invasive
Methicillin-Resistant Staphylococcus aureus Strains
Jason Yamaki,a Timothy Synold,b Annie Wong-Beringera,c
University of Southern California, Los Angeles, California, USAa; City of Hope Medical Center, Duarte, California, USAb; Huntington Hospital, Pasadena, California, USAc

We examined the effects of tigecycline on three types of exoproteins, ␣-type phenol-soluble modulins (PSM␣1 to PSM␣4), ␣-hemolysin, and protein A, in 13 methicillin-resistant Staphylococcus aureus isolates compared to those of clindamycin and linezolid. Paradoxical increases in PSM␣s occurred in 77% of the isolates with tigecycline at 1/4 and 1/8 MICs and clindamycin at
1/8 MIC compared to only 23% of the isolates with linezolid at 1/8 MIC. Induction was specific to PSM␣1 to PSM␣4, as protein A
and ␣-hemolysin production was decreased under the same conditions by all of the antibiotics used.

M

ethicillin-resistant Staphylococcus aureus (MRSA) virulence
in pneumonia and bacteremia has been attributed to exoproteins, specifically, ␣-hemolysin (Hla) and ␣-type phenol-soluble modulins (PSM␣1 to PSM␣4), which are produced by nearly
all S. aureus strains and in excess by community-acquired MRSA
strains (1). These exoproteins not only cause direct damage to
target host cells but also exacerbate the host inflammatory response, contributing to acute lung injury. Additionally, recent reports have demonstrated the importance of protein A (Spa) in
invasive diseases such as pneumonia (2, 3).
In light of the impressive arsenal of virulence factors contributing to the success of MRSA as a pathogen, it is of keen interest to
determine if anti-MRSA agents belonging to the antibiotic class of
protein synthesis inhibitors provide the added antivirulence benefit of exoprotein inhibition. In the present study, we investigated
the antivirulence potential of tigecycline, linezolid, and clindamycin which have been proven efficacious in the treatment of MRSA
infections. Our goal was to determine whether antivirulence effects can be generalized across different clinical isolates, different
agents that inhibit protein synthesis, and different exoproteins.
Specifically, we tested the effects of the above three antibiotics at
subinhibitory concentrations on formylated PSM␣1 to PSM␣4,
Hla, and Spa production by invasive MRSA isolates.
Eleven invasive MRSA isolates were tested under the following
conditions. A modified CLSI broth macrodilution assay was used
to determine MICs after 24 h of incubation at 37°C and shaking at
250 rpm in tryptic soy broth. Supernatants were then analyzed by
liquid chromatography-tandem mass spectrometry, and Hla and
Spa were analyzed by Western blotting as previously described (4,
5). Measured exotoxin values were normalized to the cell optical
density at 600 nm (OD600) at the time the supernatant was harvested. PSM␣ concentrations under various test conditions were
compared by analysis of variance with Dunn’s correction using
GraphPad Prism version 5.0 software (GraphPad, San Diego, CA).
Table 1 depicts the SCCmec type, PVL status, and baseline
PSM␣ production characteristics of the 13 isolates studied (11
clinical isolates and two control strains). The PSM␣1 to PSM␣4
peptides have been shown to cause concentration-dependent neutrophil lysis (6, 7). A PSM␣3 concentration of 5 g/ml has been
shown to lyse nearly 50% of human polymorphonuclear neutrophils (PMNs), while 10 g/ml of PSM␣1 and PSM␣4 can cause
60% and 10% PMN lysis, respectively (8, 9). Thus, isolates were
grouped on the basis of the amount of the most potent peptide,
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TABLE 1 Characteristics of the 11 clinical isolates and two control
strains used in this study
MIC (g/ml)c

PSMb
baseline

TYG

CL

LZ

Low
Medium
Low
Medium
Medium
Low
Medium
High

0.125
0.125
0.125
0.125
0.125
0.188
0.125
0.125

0.188
0.25
0.188
0.25
0.188
0.125
0.188
0.25

3
3
2
2
2
2
3
3

⫺
⫺
⫺

Blood
Blood
Blood
Blood
Blood
Pneumonia
Pneumonia
Necrotizing
pneumonia
Pneumonia
Pneumonia
Pneumonia

Very low 0.125
Very low 0.125
Very low 0.125

⬎256
⬎256
0.188

3
1
2

⫹
⫺

Wound
Blood

Medium
Low

0.25
⬎256

2
2

Isolate or strain

mec
type

PVL

Infection type

1
2
3
4
5
6
7
8

IV
IV
IV
IV
IV
IV
IV
IV

⫹
⫹
⫹
⫹
⫹
⫹
⫹
⫹

9
10
11

II
II
II

Control strains
USA300 (LAC)
USA600

IV
II

a

0.25
0.125

a
A plus or minus sign denotes the presence or absence, respectively, of the lukF/S gene,
which encodes the Panton-Valentine leukocidin.
b
The PSM␣3 production level at the baseline was arbitrarily defined as very low (⬍1
g/ml), low (1 to 5 g/ml), medium (6 to 15 g/ml), or high (⬎15 g/ml).
c
TYG, tigecycline; CL, clindamycin; LZ, linezolid. Resistance is defined as a MIC of
⬎256 g/ml (not tested for PSM␣ production at subinhibitory concentration).

PSM␣3, produced at the baseline as very low to low (ⱕ5 g/ml),
medium (6 to 15 g/ml), or high (⬎15 g/ml) producers.
Bacterial growth at 1/2 MICs of all three antibiotics was altered
in half of the isolates tested by as much as 50% of the final OD
compared to a no-antibiotic control, while no significant difference in the growth of any isolates was observed at 1/4 and 1/8
MICs. Thus, subsequent discussions will focus on the effect of
antibiotics at the latter subinhibitory concentrations that did not
affect growth. Measured PSM␣ values were normalized to the
OD600 at the time the supernatant was harvested.
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FIG 1 Overall effects of linezolid, clindamycin, and tigecycline on PSM␣1 to PSM␣4 production. (a to c) Effects of antibiotics on the production of PSM␣1 to

PSM␣4 (␣1, ␣2, ␣3, and ␣4, respectively). All measured PSM values (g/ml) were normalized to OD600 and then calculated as percentages relative to the baseline.
Isolates (n ⫽ 10) included only those that produced measureable PSM␣ peptides at the baseline (***, P ⬍ 0.0001; **, P ⬍ 0.001; *, P ⬍ 0.05). (d) Strain-to-strain
variability of PSM␣1 production at 1/8 MIC of tigecycline (TYG). Strains were grouped according to their baseline PSM␣1 production as very low (⬍1 g/ml),
low (1 to 5 g/ml), medium (6 to 15 g/ml), and high (⬎15 g/ml) producers.

Tigecycline appears to have the least inhibitory potential overall, while linezolid has the greatest (Fig. 1a to c). Increased production of all four PSM␣ peptides was the primary response observed in the presence of tigecycline at 1/4 and 1/8 MICs, while
with clindamycin this occurred only at 1/8 MIC (Fig. 1b and c).
Notably, compared to clindamycin at 1/8 MIC, which significantly
induced PSM production in seven isolates, linezolid at 1/8 MIC
modestly induced PSM production in only three isolates (Fig. 1a).
Strain-specific responses to the presence of subinhibitory antibiotic concentrations in PSM␣ production were observed. Drug
concentrations that induced PSM␣ production in some isolates
did not do so in others, independently of the baseline production
level. Specifically, with tigecycline at both 1/4 and 1/8 MICs (Fig.
1d), PSM␣1 was induced at least 1.5 times above the baseline in
77% (11/13) of the isolates, while induction did not occur in two
isolates at any of the concentrations tested. Similar results were
observed with clindamycin, where 54% (7/13) of the isolates were
induced by greater than 150%; however, this was observed only at
1/8 MIC. In those isolates, PSM␣1 production was induced to
greater than 10 g/ml, which has been shown to cause significant
PMN lysis (9). Linezolid at the same concentration resulted in
increases in PSM␣1 in only 23% (3/13) of the isolates tested, was
inhibitory in 5 isolates, and had no significant effects on the remaining isolates. Of additional interest is the observation that
nonproducers at the baseline produced PSM␣ peptides in the
presence of subinhibitory concentrations of both linezolid and
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tigecycline. However, it is noteworthy that PSM␣ production that
was induced in those two isolates did not exceed 4 g/ml and thus
would not be expected to have a significant impact on host PMNs.
In contrast to results observed with the PSM␣1 to PSM␣4 peptides, we found that the production of both Hla and Spa did not
increase under any condition and was inhibited in a dose-dependent manner at the concentrations of all three antibiotics tested
regardless of whether PSM␣ peptides were induced or suppressed
in those isolates (Fig. 2).
To our knowledge, we are the first to investigate the effect of
tigecycline on MRSA PSM␣1 to PSM␣4 peptide production. We
also included clindamycin and linezolid for comparison and
tested their antivirulence potential against two other key exotoxins, Hla and Spa. We found that at sub-MICs, agents in this class of
antibiotics have pleiotropic effects on toxin production that are
dependent on the drug, strain, and toxin tested.
All three of the antibiotics tested are known to have large volumes of distribution and would be expected to be present at high
concentrations within tissues. However, the concentrations tested
reflect clinical scenarios where sub-MICs might be achieved at
sites of infection because of inadequate dosing, altered pharmacokinetic parameters of the patient, and differential drug distribution to various body sites. Specifically, compared to the concentrations achieved at other body sites, tigecycline achieves relatively
low levels in serum (0.11 to 0.19 g/ml) and lung epithelial lining
fluid (0.11 to 0.31 g/ml), which are relevant to bacteremia and
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protein synthesis inhibitors possess inhibitory potential against all
of the exotoxins produced by S. aureus and affirm the importance
of adequate dosing.
ACKNOWLEDGMENTS
This study was supported by a research grant from Pfizer.
We thank Bixin Xi for his technical assistance in the development and
optimization of the mass spectrometry assay for PSM␣ measurement. We
also thank the Network on Antimicrobial Resistance in Staphylococcus
aureus (NARSA) and The Los Angeles County Public Health Department
for providing the control strains used.

REFERENCES
FIG 2 Effects of tigecycline on Hla and Spa production. (a) Representative
images of Western blot assays of Hla and Spa, respectively. (b and c) Production of Hla and Spa in the presence of 1/8 and 1/4 MICs of tigecycline relative
to the baseline. In no case was Hla or Spa production increased by subinhibitory concentrations of any of the antibiotics tested.

pneumonia, respectively, which are below the 0.5-g/ml FDA
MIC breakpoint of S. aureus susceptibility (10–12).
Low concentrations (1/4 and 1/8 MICs) of the antibiotics
tested were more likely to induce PSM␣ production overall, with
tigecycline having the greatest induction potential, clindamycin
having less, and linezolid even less than that. Furthermore, the
magnitudes of induction and inhibition differed among isolates,
where the same drug could induce PSM␣ production in one isolate while inhibiting production in another. The observation of
PSM␣ induction by protein synthesis-inhibiting antibiotics (e.g.,
linezolid and clindamycin) at sub-MICs is contrary to published
literature on other exotoxins, where studies have consistently
found toxin suppression under this class of antibiotics (13–16).
The production of both Hla and Spa was suppressed by antibiotics
tested at subinhibitory concentrations among the study isolates,
independently of whether PSM␣ was induced in the same isolates.
Hence, our results indicate that the induction effects may be specific for PSM␣ peptides. In contrast to our findings where significant inhibition was observed, a recent article showed tigecycline
to be minimally inhibitory of Hla and Spa production (17); however, this difference may be due to the different strains and testing
methods used.
Our study has several limitations. First, while we accounted for
changes in cell counts by normalizing the amount of toxin measured to CFU counts, other factors, such as initial slowing of
growth, could also affect toxin production. In addition, our observations are strictly in vitro and may not reflect how MRSA
strains express virulence in the host environment, where the effects of toxin induction may be mitigated by host defenses that are
present.
Further investigation is needed to examine if any other major
toxins are induced, as PSM␣ peptides did when exposed to subinhibitory concentrations of different antibiotics. Elucidating the
mechanism that underlies the induction of PSM␣ peptides is of
great interest and has implications for the future development of
new antibiotics. In light of the recent evidence implicating tigecycline in excess deaths and treatment failure in severe infections
(18), the enhanced toxin production observed in this study may
have clinical relevance and deserves further study. For now, our
data caution against the general assumption by clinicians that all

4564

aac.asm.org

1. Li M, Diep BA, Villaruz AE, Braughton KR, Jiang X, DeLeo FR,
Chambers HF, Lu Y, Otto M. 2009. Evolution of virulence in epidemic
community-associated methicillin-resistant Staphylococcus aureus. Proc.
Natl. Acad. Sci. U. S. A. 106:5883–5888.
2. Soong G, Martin FJ, Chun JR, Cohen TS, Ahn DS, Prince A. 2011.
Staphylococcus aureus protein A mediates invasion across airway epithelial
cells through activation of RhoA GTPase signaling and proteolytic activity. J. Biol. Chem. 286:35891–35898.
3. Martin FJ, Gomez MI, Wetzel DM, Memmi G, O’Seaghdha M, Soong
G, Schindler C, Prince A. 2009. Staphylococcus aureus activates type I IFN
signaling in mice and humans through the Xr repeated sequences of protein A. J. Clin. Invest. 119:1931–1939.
4. Yamaki J, Synold T, Wong-Beringer A. 2011. Antivirulence potential of
TR-700 and clindamycin on clinical isolates of Staphylococcus aureus producing phenol-soluble modulins. Antimicrob. Agents Chemother. 55:
4432– 4435.
5. Montgomery CP, Boyle-Vavra S, Daum RS. 2009. The arginine catabolic
mobile element is not associated with enhanced virulence in experimental
invasive disease caused by the community-associated methicillin-resistant
Staphylococcus aureus USA300 genetic background. Infect. Immun. 77:
2650 –2656.
6. Wang R, Braughton KR, Kretschmer D, Bach THL, Queck SY, Li M,
Kennedy AD, Dorward DW, Klebanoff SJ, Peschel A, Deleo FR, Otto
M. 2007. Identification of novel cytolytic peptides as key virulence
determinants for community-associated MRSA. Nat. Med. 13:1510 –
1514.
7. Loffler B, Hussain M, Grundmeier M, Bruck M, Holzinger D, Varga G,
Roth J, Kahl BC, Proctor RA, Peters G. 2010. Staphylococcus aureus
Panton-Valentine leukocidin is a very potent cytotoxic factor for human
neutrophils. PLoS Pathog. 6(1):e1000715. doi:10.1371/journal.ppat
.1000715.
8. Hongo I, Baba T, Oishi K, Morimoto Y, Ito T, Hiramatsu K. 2009.
Phenol-soluble modulin alpha 3 enhances the human neutrophil lysis
mediated by Panton-Valentine leukocidin. J. Infect. Dis. 200:715–723.
9. Gonzalez DJ, Okumura CY, Hollands A, Kersten R, Akong-Moore K,
Pence MA, Malone CL, Derieux J, Moore BS, Horswill AR, Dixon JE,
Dorrestein PC, Nizet V. 2012. Novel phenol-soluble modulin derivatives
in community-associated methicillin-resistant Staphylococcus aureus
identified through imaging mass spectrometry. J. Biol. Chem. 287:13889 –
13898.
10. Rodvold KA, Gotfried MH, Cwik M, Korth-Bradley JM, Dukart G,
Ellis-Grosse EJ. 2006. Serum, tissue and body fluid concentrations of
tigecycline after a single 100 mg dose. J. Antimicrob. Chemother. 58:1221–
1229.
11. Brink AJ, Bizos D, Boffard KD, Feldman C, Grolman DC, Pretorius J,
Richards GA, Senekal M, Steyn E, Welkovic N. 2010. Guideline: appropriate use of tigecycline. S. Afr. Med. J. 100:388 –394.
12. Conte JE, Golden JA, Kelly MG, Zurlinden E. 2005. Steady-state serum
and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline. Int. J. Antimicrob. Agents 25:523–529.
13. Dumitrescu O, Badiou C, Bes M, Reverdy ME, Vandenesch F, Etienne
J, Lina G. 2008. Effect of antibiotics, alone and in combination, on Panton-Valentine leukocidin production by a Staphylococcus aureus reference
strain. Clin. Microbiol. Infect. 14:384 –388.
14. Dumitrescu O, Boisset S, Badiou C, Bes M, Benito Y, Reverdy ME,
Vandenesch F, Etienne J, Lina G. 2007. Effect of antibiotics on Staphylococcus aureus producing Panton-Valentine leukocidin. Antimicrob.
Agents Chemother. 51:1515–1519.

Antimicrobial Agents and Chemotherapy

Tigecycline Induction of MRSA Phenol-Soluble Modulins

15. Stevens DL, Ma Y, Salmi DB, McIndoo E, Wallace RJ, Bryant AE. 2007.
Impact of antibiotics on expression of virulence-associated exotoxin genes
in methicillin-sensitive and methicillin-resistant Staphylococcus aureus. J.
Infect. Dis. 195:202–211.
16. Ohlsen K, Ziebuhr W, Koller KP, Hell W, Wichelhaus TA, Hacker J. 1998.
Effects of subinhibitory concentrations of antibiotics on alpha-toxin (hla)
gene expression of methicillin-sensitive and methicillin-resistant Staphylococcus aureus isolates. Antimicrob. Agents Chemother. 42:2817–2823.

September 2013 Volume 57 Number 9

17. Otto MP, Martin E, Badiou C, Lebrun S, Bes M, Vandenesch F, Etienne
J, Lina G, Dumitrescu O. 2013. Effects of subinhibitory concentrations of
antibiotics on virulence factor expression by community-acquired methicillin-resistant Staphylococcus aureus. J. Antimicrob. Chemother. 68:
1524 –1532.
18. Prasad P, Sun J, Danner RL, Natanson C. 2012. Excess deaths associated
with tigecycline after approval based on noninferiority trials. Clin. Infect.
Dis. 54:1699 –1709.

aac.asm.org 4565

